These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 9661893

  • 1. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
    Morgan RJ, Newman EM, Doroshow JH, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R.
    Cancer Res; 1998 Jul 01; 58(13):2793-800. PubMed ID: 9661893
    [Abstract] [Full Text] [Related]

  • 2. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
    McGinn CJ, Kunugi KA, Tutsch KD, Feierabend C, Alberti D, Lindstrom MJ, Wilding G, Arzoomanian RZ, Kinsella TJ.
    Clin Cancer Res; 1996 Aug 01; 2(8):1299-305. PubMed ID: 9816300
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
    Schilsky RL, Janisch L, Berezin F, Mick R, Vogelzang NJ, Ratain MJ.
    Cancer Res; 1993 Mar 15; 53(6):1293-6. PubMed ID: 7680282
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [Abstract] [Full Text] [Related]

  • 5. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
    Marshall JL, Richmond E, DeLap RJ.
    Clin Cancer Res; 1996 Sep 01; 2(9):1475-80. PubMed ID: 9816323
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C.
    Cancer Invest; 1999 Sep 01; 17(1):1-9. PubMed ID: 10999043
    [Abstract] [Full Text] [Related]

  • 7. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M, Rodriguez G, Kuhn JG, Brown T, Weiss G, MacGovren JP, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1998 Nov 01; 4(11):2763-70. PubMed ID: 9829740
    [Abstract] [Full Text] [Related]

  • 8. Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
    Garufi C, Lévi F, Giunta S, Aschelter A, Pace R, Nisticò C, Terzoli E.
    J Infus Chemother; 1995 Nov 01; 5(3 Suppl 1):134-7. PubMed ID: 8528973
    [Abstract] [Full Text] [Related]

  • 9. Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma.
    Nogué M, Seguí MA, Saigí E, Batiste-Alentorn E, Arcusa A, Boleda M, Antón I.
    Cancer; 1998 Jul 15; 83(2):254-8. PubMed ID: 9669807
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.
    Cancer Chemother Pharmacol; 2007 Feb 15; 59(3):285-93. PubMed ID: 16786333
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
    Marchbanks K, Dudley MN, Posner MR, Darnowski J.
    Pharmacotherapy; 1995 Feb 15; 15(4):451-7. PubMed ID: 7479197
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 15; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.
    Remick SC, Benson AB, Weese JL, Willson JK, Ramirez G, Wirtanen GW, Alberti DB, Nieting LM, Tutsch KD, Fischer PH.
    Cancer Res; 1989 Nov 15; 49(22):6437-42. PubMed ID: 2804987
    [Abstract] [Full Text] [Related]

  • 14. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević A.
    Srp Arh Celok Lek; 1998 Nov 15; 126(9-10):355-61. PubMed ID: 9863407
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid.
    Budd GT, Jayaraj A, Grabowski D, Adelstein D, Bauer L, Boyett J, Bukowski R, Murthy S, Weick J.
    Cancer Res; 1990 Nov 15; 50(22):7206-11. PubMed ID: 2224854
    [Abstract] [Full Text] [Related]

  • 16. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1999 Feb 15; 5(2):299-308. PubMed ID: 10037178
    [Abstract] [Full Text] [Related]

  • 17. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T, Niitani H, Furue H, Tsukagoshi S, Kanamaru R, Hasegawa K, Akazawa S, Yoneda S, Tominaga T, Sasaki T.
    Gan To Kagaku Ryoho; 1995 Feb 15; 22(2):259-71. PubMed ID: 7857102
    [Abstract] [Full Text] [Related]

  • 18. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.
    Clin Cancer Res; 2000 Oct 15; 6(10):3885-94. PubMed ID: 11051234
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
    Parulekar W, de Marsh RW, Wong R, Mendenhall W, Davey P, Zlotecki R, Berry S, Rout WR, Bjarnason GA.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1487-95. PubMed ID: 15050328
    [Abstract] [Full Text] [Related]

  • 20. [Phase I study of orally administered UFT plus l-leucovorin].
    Horikoshi N, Aiba K, Kanamaru R, Hasegawa K, Takeda S, Taguchi T, Niitani H, Furue H, Kurihara M, Ogawa M, Abe T.
    Gan To Kagaku Ryoho; 1998 Mar 01; 25(4):531-9. PubMed ID: 9530359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.